TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2325569
Drug: Rocaltrol 0.25
Normalized name: Rocaltrol 0.25mcg Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rocaltrol 0.25 micrograms twice daily
Study: 23824103
Drug: Salvage pulsed-dose-rate
Normalized name: tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Salvage pulsed-dose-rate brachytherapy (PDR-BT)
Study: 17335364
Drug: Full-mouth scaling
Normalized name: moth bean extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-mouth scaling and root planing (SRP) with azithromycin administered orally 3 days before SRP
Study: 11164856
Drug: Gemfibrozil 1200
Normalized name: Gemfibrozil
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gemfibrozil 1200 mg/day for 30 days
Study: 9182112
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil 500 mg bid
Study: 9182112
Drug: Amoxycillin/clavulanate 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxycillin/clavulanate 500 mg/125 mg tid
Study: 20926948
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg/day with standard conventional therapy (n=55)
Study: 20926948
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (n=55)
Study: 16083709
Drug: Peginterferon-alpha-2a (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon-alpha-2a (180 microg/wk) plus ribavirin (800-1200 mg/day) for 16 weeks (group A)
Study: 16083709
Drug: Peginterferon-alpha-2a (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon-alpha-2a (180 microg/wk) plus ribavirin (800-1200 mg/day) for 24 weeks (group B)
Study: 16083709
Drug: Peginterferon-alpha-2a (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon-alpha-2a (180 microg/wk) plus ribavirin (800-1200 mg/day) for 24 weeks (group C)
Study: 16083709
Drug: HCV-3 patients
Normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV-3 patients with high viral load (>800,000 IU/mL)
Study: 16083709
Drug: HCV-3 patients
Normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV-3 patients with low viral load (≤800,000 IU/mL)
Study: 10601131
Drug: Pravastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (20 to 40 mg/d)
Study: 8543490
Drug: iv meropenem
Normalized name: Meropenem
DrugBank: Meropenem (DB00760)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iv meropenem (1 g every 8 h)
Study: 8543490
Drug: iv ceftazidime
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iv ceftazidime (2 g every 8 h) plus iv amikacin (15 mg/kg/day in two or three divided doses)
Study: 2024812
Drug: Colchicine (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0.6 mg three times per day)
Study: 29523194
Drug: Chlorhexidine solution
Normalized name: CHLORHEXIDINE GLUCONATE 99.0 g in 1 L TOPICAL SOLUTION [CHLORHEXIDINE Solution]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine solution umbilical cord cleansing regimen
Study: 22564993
Drug: metformin 850
Normalized name: metFORMIN 850 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: metformin 850 mg/twice per day
Study: 16568708
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with Der p 1 standardized allergens (total dose of 10,469 UBE)
Study: 16568708
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy with Der p 1 standardized allergens
Study: 7760242
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: 10.0 g/kg/d of dextrose and 4.0 g/kg/d of fat
Study: 7760242
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: 19.0 g/kg/d of dextrose and 0.5 g/kg/d of fat
Study: 26022762
Drug: BMSC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMSC therapy
Study: 24590053
Drug: White light/240‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: White light/240‐mg caffeine (CAF)
Study: 24590053
Drug: Blue light/240‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blue light/240‐mg caffeine (BCAF)
Study: 22594651
Drug: Very low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very low nicotine content (VLNC) cigarettes plus usual Quitline care (8 weeks of NRT patches and/or gum or lozenges, plus behavioural support)
Study: 12850610
Drug: Duloxetine 40
Normalized name: duloxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 40 mg per day
Study: 12850610
Drug: Duloxetine 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 80 mg per day
Study: 10462244
Drug: Meningococcal A/C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal A/C polysaccharide vaccine (MPS)
Study: 8857079
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 12 mmol magnesium
Study: 8857079
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 24 mmol magnesium
Study: 8857079
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 4 mmol magnesium
Study: 8857079
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 8 mmol magnesium
Study: 31910279
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid and zinc supplementation (5 mg of folic acid and 30 mg of elemental zinc daily for 6 months)
Study: 23295056
Drug: Entecavir monotherapy
Normalized name: Entecavir
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir monotherapy
Study: 18682741
Drug: Triple antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple antiplatelet therapy (aspirin, clopidogrel, dipyridamole)
Study: 9391254
Drug: Intravenous octreotide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous octreotide (50 pg/h for 48 hours)
Study: 7944837
Drug: Glycosylated hemoglobin
Normalized name: Glycosylated hemoglobin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycosylated hemoglobin levels in the highest quartile at baseline (older-onset group taking insulin)
Study: 7944837
Drug: Glycosylated hemoglobin
Normalized name: Glycosylated hemoglobin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycosylated hemoglobin levels in the highest quartile at baseline (older-onset group not taking insulin)
Study: 28643427
Drug: PVR after
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVR after uroflowmetry in patients with bladder capacity >400 mL
Study: 28643427
Drug: Random PVR
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random PVR in patients with bladder capacity >400 mL
Study: 24066743
Drug: CMX001 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMX001 (100 mg twice weekly)
Study: 24066743
Drug: CMX001 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMX001 (200 mg weekly or higher)
Study: 24066743
Drug: CMX001 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMX001 (200 mg twice weekly)
Study: 12705362
Drug: L-thyroxine 8-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine 8-10 microg/kg/day in newborns
Study: 12705362
Drug: L-thyroxine 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-thyroxine 15 microg/kg/day in infants
Study: 3522407
Drug: Tinidazole (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tinidazole (single oral 2 g dose)
Study: 11229858
Drug: Antipyretic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipyretic treatment
Study: 8281625
Drug: Droloxifene 200
Normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droloxifene 200 mg
Study: 8281625
Drug: Droloxifene 300
Normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droloxifene 300 mg
Study: 2912024
Drug: vindesine 3
Normalized name: vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vindesine 3 mg/m2 weekly
Study: 2912024
Drug: spirogermanium 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: spirogermanium 80 mg/m2 three times weekly (escalated to 120 mg/m2)
Study: 1155056
Drug: Ampicillin plus
Normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ampicillin plus nasal decongestant
Study: 1155056
Drug: Cephradine plus
Normalized name: Cephradine
DrugBank: Cefradine (DB01333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cephradine plus nasal decongestant
Study: 1155056
Drug: Erythromycinestolate plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycinestolate plus nasal decongestant
Study: 28768173
Drug: NNC0090-2746 (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC0090-2746 (1.8 mg subcutaneously once daily)
Study: 28768173
Drug: Liraglutide (1.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide (1.8 mg subcutaneously once daily)
Study: 24254035
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no acupressure treatment)
Study: 19997797
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of cefmetazol on the day of surgery (group 1)
Study: 19997797
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of cefotiam for 3 days (group 2)
Study: 22524979
Drug: IV acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV acetaminophen (OFIRMEV(®); 1,000 mg, 15 minute infusion)
Study: 22524979
Drug: PO acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO acetaminophen (2 Tylenol(®) 500 mg caplets)
Study: 22524979
Drug: PR acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PR acetaminophen (2 Feverall(®) 650 mg suppositories)
Study: 12842371
Drug: Standard measles
Normalized name: MEASLES VIRUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard measles vaccine (control)
Study: 10471182
Drug: Vaxigrip injection
DrugBank: Haemagglutinin-strain B (DB15482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaxigrip injection
Study: 2190758
Drug: Hydrocolloid dermatologic
Normalized name: psyllium hydrocolloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocolloid dermatologic patch (Actiderm) plus topical beta‐methasone valerate 0.1 percent cream
Study: 2190758
Drug: Topical beta‐methasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical beta‐methasone valerate 0.1 percent cream alone
Study: 2190758
Drug: Hydrocolloid dermatologic
Normalized name: psyllium hydrocolloid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocolloid dermatologic patch (Actiderm) alone
Study: 27252754
Drug: Fifth generation
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fifth generation bonding agent
Study: 27252754
Drug: Seventh generation
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seventh generation bonding agent
Study: 23945138
Drug: WalkLink+: prompted
Approvals — FDA: no, EMA: no, PMDA: no
Description: WalkLink+: prompted and provided feedback on participants' online and in‐person social‐network interactions to expand networks for PA, plus provided evidence‐based online walking program and weekly walking tips
Study: 23945138
Drug: WalkLink: evidence‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: WalkLink: evidence‐based online walking program and weekly tips only
Study: 23945138
Drug: Minimal Treatment
Normalized name: Minimally modified low density lipoprotein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal Treatment Control: weekly tips only
Study: 20584793
Drug: Injection plus
Normalized name: Bimectin Plus Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection plus exercise
Study: 10971105
Drug: 0.5 IU/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 IU/kg per week subcutaneous recombinant human GH
Study: 10971105
Drug: 1.0 IU/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 IU/kg per week subcutaneous recombinant human GH
Study: 10971105
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of GH
Study: 8569467
Drug: Prednisone (CS)
Normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone (CS) + oral cyclophosphamide (CYC) + plasma exchanges (PE)
Study: 8569467
Drug: CS +
Normalized name: Culturelle Probiotics + Multivitamin Gummies (Mixed Berry)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CS + oral CY
Study: 31952938
Drug: Probiotics (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics (5 × 10^9 cfu/capsule)
Study: 27214145
Drug: Inhaled, nebulized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled, nebulized AZD5423 at doses of at least 300 μg for 2 weeks
Study: 27214145
Drug: Inhaled, nebulized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled, nebulized AZD5423
Study: 24862742
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of oral MPH
Study: 10658377
Drug: Optimal protamine
Normalized name: protamines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal protamine dose determined for residual heparin concentration (P group)
Study: 10658377
Drug: Initial fixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Initial fixed dose of protamine, 1.67 mg protamine per milligram total heparin (C group)
Study: 8557059
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg salbutamol
Study: 2095163
Drug: Placebo (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (200 ml of 2% glucose solution)
Study: 6985882
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day of UDCA
Study: 6985882
Drug: 150 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg/day of UDCA
Study: 31899739
Drug: Osteoblastic cell
Normalized name: Human allogeneic bone marrow derived osteoblastic cells
DrugBank: Human allogeneic bone marrow derived osteoblastic cells (DB17890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteoblastic cell therapy
Study: 31899739
Drug: BMAC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMAC treatment
Study: 31158840
Drug: Bardoxolone methyl
Normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bardoxolone methyl 20 mg
Study: 31158840
Drug: Bardoxolone methyl
Normalized name: Bardoxolone methyl
DrugBank: Bardoxolone methyl (DB05983)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bardoxolone methyl 80 mg
Study: 25816354
Drug: SQ-LNS without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SQ-LNS without zinc, placebo tablet
Study: 25816354
Drug: SQ-LNS containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ-LNS containing 5mg zinc, placebo tablet
Study: 25816354
Drug: SQ-LNS containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ-LNS containing 10mg zinc, placebo tablet
Study: 25816354
Drug: SQ-LNS without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SQ-LNS without zinc and 5mg zinc tablet
Study: 21415814
Drug: Ambulatory blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambulatory blood pressure monitoring on two occasions, 7-15 days apart, on a stable antihypertensive regimen.
Study: 8182996
Drug: Prophylaxis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis with antacids and H2 blockers (AA+H2)
Study: 23887932
Drug: Complicated grief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complicated grief group therapy (CGGT)
Study: 23887932
Drug: Standard group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard group therapy (treatment as usual [TAU])
Study: 20357174
Drug: 54 mg
Normalized name: aspirin 454 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 54 mg of genistein aglycone daily (n = 71)
Study: 11029334
Drug: 400 microgram
Normalized name: Fentanyl 400 microgram buccal film
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 microgram orally inhaled budesonide plus 200 microgram intranasal budesonide (BUD)
Study: 11029334
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral montelukast plus 10 mg oral cetirizine (ML + CZ)
Study: 8610727
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration (usual dose)
Study: 8610727
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration (1.75-fold dose)
Study: 8610727
Drug: Implantable pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable pump therapy (1.75-fold dose)
Study: 8610727
Drug: Implantable pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implantable pump therapy (usual dose)
Study: 3914839
Drug: Tamoxifen (secondary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen (secondary therapy)
Study: 3914839
Drug: Estrogen (secondary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen (secondary therapy)
Study: 3695527
Drug: Chemotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy with Dacarbazine (DTIC) 200 mg/M2 I.V. daily X 5 every 4 weeks and Estracyt 15 mg/kg orally daily for 1 year
Study: 3695527
Drug: Immunotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy with TICE BCG 1 ml to an area of scarification near the primary site, every 4 weeks for 1 year
Study: 17024871
Drug: Postoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiation therapy (PORT)
Study: 12137243
Drug: Inhalation challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation challenge with (1‐‐>3)‐beta‐D‐glucan
Study: 12137243
Drug: Saline inhalation
Normalized name: Broncho Saline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline inhalation challenge
Study: 29119296
Drug: Steroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid injection (1 ml of Depo-Medrol, 40 mg)
Study: 18672763
Drug: Shexiang Baoxin
Normalized name: CAMPHOR (NATURAL) 30.53 mg / MENTHOL 40.71 mg / METHYL SALICYLATE 25.95 mg TOPICAL PLASTER [SheXiang ZhuangGu Gao]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shexiang Baoxin Pill (SBP) 2 pills, taken orally three times per day for 6 months
Study: 18672763
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy for CHD (anti-platelet, lipid regulating, anti-ischemia)
Study: 16898535
Drug: Steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid treatment (60 mg/m2/48h) in children in relapse (Group A, n=24)
Study: 16898535
Drug: Steroid treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid treatment (30 mg/m2/48h) in children in remission (Group B, n=20)
Study: 16898535
Drug: No steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No steroid treatment in children in remission (Group C, n=22)
Study: 2011407
Drug: Ciprofloxacin (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin (750 mg b.i.d.)
Study: 2011407
Drug: Amoxicillin +
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxicillin + clavulanic acid or erythromycin
Study: 24249544
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose trivalent inactivated influenza vaccine (60 µg)
Study: 24249544
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose trivalent inactivated influenza vaccine (15 µg)
Study: 22017808
Drug: Mindfulness-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based cognitive therapy plus treatment as usual (MBCT+TAU)
Study: 11910270
Drug: Metergoline 8
Normalized name: Metergoline
DrugBank: Metergoline (DB13520)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metergoline 8 mg
Study: 11910270
Drug: Bright artificial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bright artificial light treatment after 2 weeks
Study: 18158176
Drug: Specific oral
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific oral tolerance induction (SOTI)
Study: 3593481
Drug: Acute alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute alcohol consumption (0.4 g/kg orally)
Study: 3593481
Drug: Standard (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard (75 g) glucose tolerance test
Study: 27697397
Drug: 2 implant‐supported‐overdentures
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 implant‐supported‐overdentures on two tissue‐level implants
Study: 27697397
Drug: 4 implant‐supported‐overdentures
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 implant‐supported‐overdentures on four tissue‐level implants
Study: 24818861
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural treatment programme (CONECSI)
Study: 22566279
Drug: Group acceptance
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group acceptance and commitment therapy (ACT) informed stress management intervention
Study: 16485515
Drug: Perindopril 8
Normalized name: perindopril 8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril 8 mg/day for 1 year
Study: 9279673
Drug: Flurbiprofen 0.03%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen 0.03% ophthalmic solution
Study: 9279673
Drug: Indomethacin 1.0%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 1.0% ophthalmic solution